Cart
sales@molnova.com
Abl Cytosolic Substrate
CAS No. 168202-46-8
Abl Cytosolic Substrate( —— )
Catalog No. M30182 CAS No. 168202-46-8
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbl Cytosolic Substrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
-
DescriptionAbl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number168202-46-8
-
Formula Weight1336.58
-
Molecular FormulaC64H101N15O16
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Glu}{Ala}{Ile}{Tyr}{Ala}{Ala}{Pro}{Phe}{Ala}{Lys}{Lys}{Lys}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Buchdunger E, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996 Jan 1;56(1):100-4.
molnova catalog
related products
-
Dasatinib
A potent, orally bioavailable, dual Src/Abl kinase inhibitor.
-
Vamotinib
Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis.
-
N-Desmethyl imatinib
N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
